2022 was another big year for Shockwave and Q4 was no exception! On Twitter, the first Shockwave L6 cases were posted by physicians who participated in its limited release and it was great to see their excitement for our new large-vessel peripheral IVL catheter launching soon in the U.S.! At VIVA ‘22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study; this larger patient data set reinforces the predictability of Shockwave IVL and its ability to consistently modify calcium across vessel beds, challenging lesions and complex patients. Additionally, international calcium experts shared their real-world experiences with the safety and efficacy of coronary IVL across different calcium morphologies, including concentric, eccentric and nodular calcium. Check out that and more in the new PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
In a late-breaking clinical trial session at VIVA22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study (OS). PAD III OS represents the largest prospective ‘real-world’ evidence for the treatment of complex, heavily calcified peripheral artery disease. Building on the interim results presented at VIVA21, this larger patient data set reinforces the predictability of IVL and its ability to consistently modify calcium across vessel beds, challenging lesions, and complex patients (CLI, dialysis, and female patients). These real-world outcomes mirror the previously reported PAD III Randomized-Controlled Trial showing that IVL safely and effectively modifies challenging calcium in complex patients.
Check-out the presentation below and hear from Dr. Armstrong on the importance of the largest prospective ‘real-world’ data set in the treatment of heavily calcified PAD.
Read More
Topics:
Peripheral IVL,
Peripheral Conferences,
Peripheral Clinical Data,
Shockwave M5 & Shockwave M5+
It was smooth sailing for Shockwave this summer! Thank you to everyone who made Q3 unforgettable; but before we get cozy for the holidays, let’s reflect on the events that made the quarter one to remember. This year’s TCT was particularly momentous, as we announced the first prospective, female-only study of coronary interventions, EMPOWER CAD. We also explored tips and tricks for IVL with guide extension catheter usage with Dr. Stephan Heo and debated different approaches to modifying nodular calcium with an expert panel. Read up on the latest Shockwave IVL peer-written publications and more in the Q3 PulsePoint Newsletter.
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Female vs. Male Outcomes,
Empower CAD
Join us in Las Vegas for VIVA 2022 as we crack into late breaking data supporting IVL’s consistency in calcium modification in real-world PAD. The late breaker, presented by Dr. Ehrin Armstrong, features the final 1,373 patient cohort datafrom the Disrupt PAD III Observational Study. Following the data release, an esteemed panel will discuss IVL’s consistent outcomes from both real-world AND randomized studies. Don’t roll the dice with calcium modification and join us at VIVA2022!
Read More
Topics:
Peripheral IVL,
IVL Technology,
Peripheral Conferences,
Peripheral Clinical Data
At AMP 2022, Dr. Peter Soukas presented the largest set of real-world data on Shockwave IVL in CLI patients. These data include results from patient groups historically not included in other PAD studies, such as Rutherford 6 and dialysis patients, and patients with single or absent vessel run-off. These data show the significant reduction of stenosis post-IVL in these patients, the minimal complications and the consistent results across multiple vessel beds. In this presentation Dr. Soukas shares why these data are important for physicians who treat CLI, and how his calcium modification algorithm has changed over time with IVL.
Read More
Topics:
Peripheral IVL,
Peripheral Conferences,
Peripheral Clinical Data,
Shockwave M5 & Shockwave M5+
Calcified lesions in CLTI patients pose a number of hurdles for endovascular therapy including acute and sub-acute recoil, flow-limiting dissections and distal embolization. In this presentation from Charing Cross 2022 Dr. Thulasidasan shares how Shockwave IVL has improved his treatment for CLTI patients with low complications and increased durability. Dr. Thulasidasan walks through case examples with IVL in CLTI patients and states how the data supporting IVL backs up what he’s seeing in practice.
Read More
Topics:
Peripheral IVL,
Peripheral Conferences,
Peripheral Clinical Data
In this three-episode tutorial series, Dr Stefano Fazzini and Dr Michel Bosiers provide an excellent overview on how IVL removes the barriers of calcified hostile access and expands treatment boundaries in EVAR and TEVAR procedures by changing vessel compliance, facilitating luminal gain and significantly reducing complications.
Read More
Topics:
Peripheral IVL,
Peripheral Clinical Data
It’s no exaggeration that calcium represents the Achilles heel of endovascular treatment. As the patient population continues to evolve in complexity we need solutions that can treat severe calcified disease in an efficacious, safe and durable way. Listen as Dr Konstantinos Stavroulakis shares the outcomes of his recent publication of Intravascular Lithotripsy (IVL) and DCB in severely calcified femoropopliteal lesions followed out to 12 months and understand why he believes IVL is a game changer in the treatment of complex real world patients.
Read More
Topics:
Peripheral IVL,
Peripheral Clinical Data
The presence of calcium can pose significant challenges in achieving optimal procedural outcomes in PAD treatment and can pose as a barrier to the delivery of large bore access devices. Shockwave IVL is shifting the paradigm in the way physicians approach calcium by simplifying procedures in an efficacious and safe manner. Now the next generation of peripheral IVL technology is here: Shockwave M5+! The Shockwave M5+ extends treatment options with the introduction of its new features; faster pulsing, an extended working length and expanded size matrix.
Read More
Topics:
Peripheral IVL,
Peripheral Clinical Data,
Shockwave M5 & Shockwave M5+
Alternative access strategies in TAVI are prone to higher complication rates when compared to transfemoral access. This leads to the question; should physicians tackle difficult transfemoral over alternative access?
Read More
Topics:
Peripheral IVL,
Peripheral Conferences,
Peripheral Clinical Data
